Mereo BioPharma Group plc Banner Image

Mereo BioPharma Group plc

  • Ticker MREO
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Mereo BioPharma Group plc Logo Image
  • 11-50 Employees
  • Based in London, England
Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Mereo's lead oncology product candidate, etigilimab ("Anti-TIGIT"), has completed a Phase 1a dose escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b studyMore in combination with nivolumab in select tumor types. Mereo's rare disease product portfolio consists of setrusumab, which has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta ("OI"), as well as alvelestat, which is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency ("AATD") and in a Phase 1b/2 clinical trial in COVID-19 respiratory disease.
Mereo BioPharma Group plc

Most Recent Annual Report

Mereo BioPharma Group plc
MOST RECENT 2021 Annual Report

Older/Archived Annual Reports